Trial Profile
A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients With Cystic Fibrosis Treated With Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors(The CF-FC Study)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 10 Dec 2021
Price :
$35
*
At a glance
- Drugs Pancrelipase (Primary)
- Indications Exocrine pancreatic insufficiency
- Focus Adverse reactions
- Acronyms The CF-FC Study
- Sponsors Abbott Laboratories; AbbVie
- 21 Jul 2020 Status changed from recruiting to discontinued.
- 30 Aug 2017 Planned End Date changed from 31 Jul 2022 to 29 Jul 2022.
- 30 Aug 2017 Planned primary completion date changed from 31 Jul 2022 to 29 Jul 2022.